Literature DB >> 18356783

Effect of nephrology referral on the initiation of haemodyalisis and mortality in ESRD patients.

G Selim1, O Stojceva-Taneva, M Polenakovic, Lj Georgievska-Ismail, S Gelev, E Hristova-Antova, V Andova, P Dzekova, A Sikole.   

Abstract

Late nephrology referral of patients with chronic kidney disease (CKD) has been suggested as increasing mortality after the initiation of dialysis. The aim of this study was to assess the impact of nephrology referral on the initiation of haemodyalisis (HD) and mortality during HD treatment in end-stage renal disease (ESRD) patients who have died in our institution over a five-year period. We studied data from all 117 patients on HD treatment in our institution who died (after 90 days of HD treatment) in the period between 01.01. 2002 and 31.12. 2006. Early (ER) and late referral (LR) were defined by the time of follow-up by a nephrologist greater than or less than 6 months, respectively, before the initiation of haemodialysis. Out of a total of 117 patients, 37.6% (44 patients) started HD in the ER group and 62.4% (73 patients) in the LR group. At the start of HD, LR patients were older, had a higher proportion of temporary catheters and had a significantly lower levels of haemoglobin and diuresis. Creatinine clearance was less in the LR (7.67 +/- 3.86 ml/min/1.73 m2) vs. the ER group (8.70 +/- 3.62 ml/min/1.73 m2), but not significantly different. Cardiovascular disease (CVD), defined by a history of myocardial infarction, cerebral vascular disease, peripheral arteriopathy, and/or heart failure, was also significantly more common among LR patients compared to ER (56%; 27%, p = 0.002). During the haemodyalisis treatment, the LR group had significantly lower levels of haemoglobin and haematocrit. CVD accounted for about 64% of deaths observed in the LR group. According to echocardiography data, there were no significant differences in the left ventricular mass index (LVMI) between the LR and ER groups at the time of dialysis initiation, but during haemodialysis treatment the LR group had significantly greater LVMI than the ER group (232,96 +/- 92,48 g/m2 vs.184,09 +/- 51,74 g/m2; p = 0,031). The time until death in months during dialysis treatment was significantly different between the LR and ER group, (69.51 +/- 64.03 vs.113.27 +/- 89.03, p = 0.0025). LR patients experienced a greater degree of anaemia and a high prevalence of CVD at the time of dialysis initiation. Our data suggest that the anaemia, CV damage and progression of left ventricular hypertrophy (LVH) in the LR patients during haemodialysis treatment are associated with poor survival on haemodialysis.

Entities:  

Mesh:

Year:  2007        PMID: 18356783

Source DB:  PubMed          Journal:  Prilozi        ISSN: 0351-3254


  4 in total

1.  Comparative effectiveness of early versus conventional timing of dialysis initiation in advanced CKD.

Authors:  Deidra C Crews; Julia J Scialla; L Ebony Boulware; Sankar D Navaneethan; Joseph V Nally; Xiaobo Liu; Susana Arrigain; Jesse D Schold; Patti L Ephraim; Stacey E Jolly; Stephen M Sozio; Wieneke M Michels; Dana C Miskulin; Navdeep Tangri; Tariq Shafi; Albert W Wu; Karen Bandeen-Roche
Journal:  Am J Kidney Dis       Date:  2014-02-06       Impact factor: 8.860

2.  Timing of nephrology referral and initiation of dialysis as predictors for survival in hemodialysis patients: 5-year follow-up analysis.

Authors:  Gjulsen Selim; Olivera Stojceva-Taneva; Goce Spasovski; Liljana Tozija; Risto Grozdanovski; Ljubica Georgievska-Ismail; Beti Zafirova-Ivanovska; Pavlina Dzekova; Lada Trajceska; Saso Gelev; Daniela Mladenovska; Aleksandar Sikole
Journal:  Int Urol Nephrol       Date:  2014-08-07       Impact factor: 2.370

3.  'Reality and desire' in the care of advanced chronic kidney disease.

Authors:  Belén Marrón; Lourdes Craver; César Remón; Mario Prieto; Josep M Gutiérrez; Alberto Ortiz
Journal:  NDT Plus       Date:  2010-06-28

4.  Factors Associated with the Choice of Peritoneal Dialysis in Patients with End-Stage Renal Disease.

Authors:  Pei-Chun Chiang; Jia-Jeng Hou; Ing-Ching Jong; Peir-Haur Hung; Chih-Yen Hsiao; Tsung-Liang Ma; Yueh-Han Hsu
Journal:  Biomed Res Int       Date:  2016-03-06       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.